Literature DB >> 30168768

Treatment of Dupuytren's contracture: a systematic review.

E Soreide1, M H Murad2, J M Denbeigh3, E A Lewallen4, A Dudakovic3, L Nordsletten5, A J van Wijnen6, S Kakar3.   

Abstract

Aims: Dupuytren's contracture is a benign, myoproliferative condition affecting the palmar fascia that results in progressive contractures of the fingers. Despite increased knowledge of the cellular and connective tissue changes involved, neither a cure nor an optimum form of treatment exists. The aim of this systematic review was to summarize the best available evidence on the management of this condition. Materials and
Methods: A comprehensive database search for randomized controlled trials (RCTs) was performed until August 2017. We studied RCTs comparing open fasciectomy with percutaneous needle aponeurotomy (PNA), collagenase clostridium histolyticum (CCH) with placebo, and CCH with PNA, in addition to adjuvant treatments aiming to improve the outcome of open fasciectomy. A total of 20 studies, involving 1584 patients, were included.
Results: PNA tended to provide higher patient satisfaction with fewer adverse events, but had a higher rate of recurrence compared with limited fasciectomy. Although efficacious, treatment with CCH had notable recurrence rates and a high rate of transient adverse events. Recent comparative studies have shown no difference in clinical outcome between patients treated with PNA and those treated with CCH.
Conclusion: Currently there remains limited evidence to guide the management of patients with Dupuytren's contracture. Cite this article: Bone Joint J 2018;100-B:1138-45.

Entities:  

Keywords:  Clinical outcome; Dupuytren’s contracture; Dupuytren’s disease; Management; Systematic review; Treatment

Mesh:

Substances:

Year:  2018        PMID: 30168768     DOI: 10.1302/0301-620X.100B9.BJJ-2017-1194.R2

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  9 in total

1.  Could coenzyme Q10 be the treatment for Dupuytren's disease?

Authors:  Wilma Lourens
Journal:  BMJ Case Rep       Date:  2019-03-01

Review 2.  Dupuytren's Disease-Etiology and Treatment.

Authors:  Mike Ruettermann; Robert Michael Hermann; Karl Khatib-Chahidi; Paul M N Werker
Journal:  Dtsch Arztebl Int       Date:  2021-11-19       Impact factor: 8.251

3.  Treatment of Dupuytren's Contracture With Collagenase: A Systematic Review.

Authors:  Alexis B Sandler; John P Scanaliato; Thomas Dennis; Gilberto A Gonzalez Trevizo; Sorana Raiciulescu; Leon Nesti; John C Dunn
Journal:  Hand (N Y)       Date:  2021-01-21

4.  Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: 2-Year Follow-up.

Authors:  Suresh K Nayar; Dennis Pfisterer; John V Ingari
Journal:  Clin Orthop Surg       Date:  2019-08-12

5.  Cost-effectiveness of Recurrent Dupuytren Contracture Treatment.

Authors:  Alfred P Yoon; Robert L Kane; David W Hutton; Kevin C Chung
Journal:  JAMA Netw Open       Date:  2020-10-01

6.  Versatility of percutaneous needle fasciotomy for Dupuytren's disease across a spectrum of disease severity: A single-surgeon experience of 118 rays.

Authors:  Manal I A Patel; Irshad A Patel
Journal:  JPRAS Open       Date:  2020-11-30

Review 7.  Scoping review and interpretation of myofascial pain/fibromyalgia syndrome: An attempt to assemble a medical puzzle.

Authors:  Shiloh Plaut
Journal:  PLoS One       Date:  2022-02-16       Impact factor: 3.240

8.  Epineural Methylene Blue Injection May Aid Localization of Digital Nerves in Dupuytren's Surgery.

Authors:  Tamás Szabó; Viktória Kormos; Zoltán Rékási; Balázs Gaszner
Journal:  Eur Surg Res       Date:  2021-10-22       Impact factor: 1.114

9.  Serious complications and risk of re-operation after Dupuytren's disease surgery: a population-based cohort study of 121,488 patients in England.

Authors:  Osaid Alser; Richard S Craig; Jennifer C E Lane; Albert Prats-Uribe; Danielle E Robinson; Jonathan L Rees; Daniel Prieto-Alhambra; Dominic Furniss
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.